Novartis received approval from the European Commission to market the drug everolimus in the treatment of patients with neuroendocrine tumors of the pancreas in an advanced stage.
The authorization is based on the results of Phase III clinical tests have shown that everolimus reduced by 65% the risk of progression of this tumor compared to a placebo.
'A consistent improvement in survival without disease progression was observed with everolimus in each subgroup of patients, including those who have not received chemotherapy earlier', says the Swiss pharmaceutical company.
The decision applies to Brussels 27 member countries of the European Union, plus Iceland and Norway.
Save Money On Your Power Bill By Unplugging These Gadgets At Night
-
Want to shrink your power bill? Some everyday gadgets quietly drain energy
all night long; you'll be surprised which ones make the list.
3 hours ago
